Humacyte三季度财报：Symvess收入同比翻倍还多 商业化推广继续扩大
总部位于北卡罗来纳州达勒姆的生物科技公司Humacyte于11月10日公布了截至2026年9月30日的第三季度财报，旗下产品Symvess的收入比上年同期增长了一倍还多，商业化推广范围继续扩大。
公司表示，用于透析通路的无细胞组织工程血管ATEV的补充生物制品许可申请（sBLA）正按计划推进，预计在2026年11月内向美国食品药品监督管理局（FDA）提交。
Humacyte还在2026年11月启动了CTEV用于冠状动脉搭桥手术的首个人体二期a临床研究，首个临床试验点已经激活。公司在11月7日至8日举行的美国心脏协会科学年会上就CTEV做了三场报告。Humacyte于11月10日上午8时（美东时间）举行电话会议，向投资者介绍第三季度业绩与业务进展。Humacyte是一家处于商业化阶段的生物技术平台公司，致力于开发可普遍植入的生物工程人体组织。
Humacyte Q3 Results: Symvess Revenue More Than Doubles as Commercial Adoption Expands
Durham, North Carolina-based biotechnology company Humacyte reported results for the third quarter ended September 30, 2026, on November 10, with revenue from its Symvess product more than doubling from a year earlier and commercial adoption continuing to expand.
The company said the supplemental biologics license application (sBLA) for its acellular tissue-engineered vessel (ATEV) for dialysis access is on track and is expected to be submitted to the U.S. Food and Drug Administration (FDA) within November 2026.
Humacyte also started the first-in-human Phase 2a clinical study of CTEV for coronary artery bypass grafting in November 2026, with the first clinical trial site activated. The company presented three reports on CTEV at the American Heart Association’s Scientific Sessions on November 7-8. Humacyte held a conference call at 8 a.m. Eastern on November 10 to discuss third-quarter results and business progress with investors. Humacyte is a commercial-stage biotechnology platform company developing universally implantable bioengineered human tissues.
来源：GlobeNewswire
发布：GSM·美国（发布链接）
图片来源：实验室资料图。（Pexels）
GSM Global · 本篇英文版 English edition of this story
